1.
Acta Biomed
; 93(4): e2022266, 2022 Aug 31.
Article
in English
| MEDLINE | ID: covidwho-2026276
2.
Acta Biomed
; 92(S6): e2021455, 2021 10 01.
Article
in English
| MEDLINE | ID: covidwho-1503761
ABSTRACT
The COVID-19 pandemic era is causing a relevant issue for the health. There is no specific drug able to antagonize the SARS-CoV-2 infection. As a consequence, there is growing interest about potential molecules able to contrast infection. In this regard, HMGB, an alarmin, may play a relevant role in pathogenic mechanisms induced by SARS-CoV-2. As HMGB1 is antagonized by glycyrrhizin, this substance could be potentially useful as ancillary treatment in COVID-19.
Subject(s)
COVID-19 , HMGB1 Protein , Glycyrrhizic Acid/pharmacology , Humans , Pandemics , SARS-CoV-2
3.
Int. arch. otorhinolaryngol. (Impr.)
; 24(3):388-390, 2020.
Article
in English
| LILACS (Americas) | ID: grc-742567
4.
Int Arch Otorhinolaryngol
; 24(3): e388-e390, 2020 Jul.
Article
in English
| MEDLINE | ID: covidwho-696313